SYFOVRE™-PEGCETACOPLAN INJECTION

SYFOVRE™ is a new FDA-approved drug from Apellis Pharmaceuticals that can slow the progression of visual damage caused by Dry Age-related Macular Degeneration with geographic atrophy. The development of SYFOVRE™ is an important step for patients living with Dry AMD with GA as there is no other drug that has proven in clinical trials to slow down the progression of geographic atrophy. Which is the major cause of vision acuity in patients with Dry Age-related Macular Degeneration. To discuss the pros and cons of this innovative treatment, please contact the office at 607-770-9000 to set up a time to discuss this with Dr. Sperber.

https://ml-eu.globenewswire.com/Resource/Download/f1e71507-4c4d-45f5-a748-ce0bc930a5a9